StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SUPNBullishAnalyst Target Updateanalyst
Medium materiality6/10

Piper Sandler Resumes Supernus Pharmaceuticals at Overweight

Nov 4, 2026, 3:30 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Bullish analyst initiation, with substantial stated target upside; treat as opinion-based rather than a confirmed catalyst.

AI summary

What happened, with direct paths to the underlying reporting

Piper Sandler resumed coverage of SUPN with an Overweight rating and a $47 target, about 67% above the posted price of $28.15. The target is an analyst opinion, not a forecast guarantee.

  • Overweight rating; $47 target versus $28.15 posted price.

Key facts

  1. 01

    Target: $47

  2. 02

    Posted price: $28.15

  3. 03

    Analyst firm: Piper Sandler

  4. 04

    Analyst: David Amsellem

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.